Preview Mode Links will not work in preview mode

This Week in Cardiology

Nov 12, 2021

Left atrial appendage closure vs DOACs, TAVR vs SAVR, renal denervation, and an AHA 2021 preview are the topics John Mandrola, MD, discusses in this week’s podcast. To read a partial transcript or to comment, visit:


- PRAGUE-17: LAA Closure Holds Up Against DOACs Out to 4 Years

- LAAO vs DOAC: PRAGUE-17 Falls Short

- Left Atrial Appendage Closure versus Non-Warfarin Oral Anticoagulation in Atrial Fibrillation: 4-Year Outcomes of PRAGUE-17

- Does Percutaneous Left Atrial Appendage Closure Stand the Test of Time?


- SURTAVI at 5 Years Reinforces TAVR but Was It Long-term Enough?

- Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients

III - Renal Denervation

- Renal Denervation Adds Clout to BP Meds in Resistant HTN: RADIANCE-HTN TRIO

- Renal Denervation Remains Only Promising in Meta-Analysis

- Renal Denervation for Hypertension: A Systematic Review and Meta-Analysis of Randomized, Blinded, Placebo-Controlled Trials

IV - AHA Preview

- AHA 2021 Puts Scientific Dialogue, Health Equity Center Stage

- Mandrola Previews the Virtual AHA 2021

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact